StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright dropped their target price on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th.
Read Our Latest Stock Report on Minerva Neurosciences
Minerva Neurosciences Stock Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). As a group, analysts predict that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Articles
- Five stocks we like better than Minerva Neurosciences
- When to Sell a Stock for Profit or Loss
- Global Lithium Demand Soars: Top 3 Stocks Positioned to Gain
- Do ETFs Pay Dividends? What You Need to Know
- Oil Prices Fall, Sector Pulls Back: Time to Buy this Stock?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- AI Boom Fuels Demand for Dominion Energy Stock
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.